Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102323212 | 10232321 | 2 | F | 20160808 | 20140612 | 20160812 | EXP | FR-ROCHE-1416214 | ROCHE | . HIGHLIGHT ON DPYD GENE POLYMORPHISMS AND TREATMENT BY CAPECITABINE. SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION 2016 JUL 20;:1-4. | 0.00 | F | Y | 0.00000 | 20160812 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102323212 | 10232321 | 1 | PS | CAPECITABINE. | CAPECITABINE | 1 | Oral | 20896 | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 102323212 | 10232321 | 1 | Breast cancer metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 102323212 | 10232321 | OT |
| 102323212 | 10232321 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 102323212 | 10232321 | Death | |
| 102323212 | 10232321 | Diarrhoea | |
| 102323212 | 10232321 | Gastrointestinal toxicity | |
| 102323212 | 10232321 | Haematotoxicity | |
| 102323212 | 10232321 | Neurotoxicity | |
| 102323212 | 10232321 | Palmar-plantar erythrodysaesthesia syndrome | |
| 102323212 | 10232321 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |